Journal of acquired immune deficiency syndromes (1999)最新文献

{"title":"Anal Cancer Screening in People Living with HIV: A Pilot Study of Primary HPV Screening with Triage Use of p16/Ki67 Dual Stain.","authors":"Ian K J Wong, Clare E F Dyer, Andrew E Grulich, Fengyi Jin, Carmella Law, Mark N Polizzotto, Mark Bloch, Rick Varma, Melissa L Kelly, Jennifer M Roberts, Richard J Hillman, I Mary Poynten","doi":"10.1097/QAI.0000000000003731","DOIUrl":"https://doi.org/10.1097/QAI.0000000000003731","url":null,"abstract":"<p><strong>Background: </strong>and setting: People living with HIV (PLHIV), especially gay, bisexual, and other men who have sex with men (GBM), are at increased risk of anal cancer. A recent randomised controlled trial showed treating anal high-grade squamous intraepithelial lesions (HSIL) reduces anal cancer incidence, supporting development of screening programs. Given the transition from cytological to HPV testing in cervical cancer screening, HPV testing for anal cancer is worth investigating. However, due to its low specificity, additional biomarkers like the p16/Ki67 dual stain may improve specificity.</p><p><strong>Methods: </strong>In this multicentre pilot study, PLHIV aged 35+ were recruited from sexual health centres and a general practice. Participants underwent digital anorectal examination (DARE) and anal swab collection for HPV and p16/Ki67 dual stain testing. High-resolution anoscopy (HRA) referrals were based on screening results at baseline and 12 months, with immediate HRA referral for HPV16-positive participants. The primary objective was to assess adherence to the screening program.</p><p><strong>Results: </strong>From October 2019 to July 2021, 136 participants (median age 54) were recruited. Overall, 85.3% completed all screening and HRA steps, with 92.8% attending HRA referrals. At baseline, 71.4% had anal high-risk HPV (HRHPV), with 40 testing positive for HPV16. Of those with HRHPV, 42.1% had a positive p16/Ki67 dual stain, while 37.9% had unsatisfactory results. Among 37 HRA attendees, 73.0% had composite cytological/histological HSIL. At 12 months, 81.4% tested positive for HRHPV, and 25.9% had composite HSIL.</p><p><strong>Conclusions: </strong>Adherence to the screening algorithm was 85.3%, with >90% attendance at HRA referrals. Screening identified composite HSIL in 53.1% of participants. Utility of the p16/Ki67 dual stain remains undetermined due to high rates of unsatisfactory samples.</p>","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144736557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Following Diagnosis of HIV-Associated Kaposi Sarcoma Among Adults in East Africa in the \"Treat-All\" Era.","authors":"Helen Byakwaga, Aggrey Semeere, Miriam Laker-Oketta, Naftali Busakhala, Esther Freeman, Elyne Rotich, Megan Wenger, Philippa Kadama-Makanga, Job Kisuya, Matthew Semakadde, Bronia Mwine, Charles Kasozi, Bwana Mwebesa, Toby Maurer, David V Glidden, Kara Wools-Kaloustian, Andrew Kambugu, Jeffrey Martin","doi":"10.1097/QAI.0000000000003733","DOIUrl":"https://doi.org/10.1097/QAI.0000000000003733","url":null,"abstract":"<p><strong>Background: </strong>HIV-associated Kaposi sarcoma (KS) remains among the most common malignancies in sub-Saharan Africa in the \"Treat All\" era. Survival after KS diagnosis has historically been poor in Africa, but knowledge whether survival has changed in the contemporary era has been limited by lack of community-representative surveillance and monitoring systems.</p><p><strong>Methods: </strong>We identified people living with HIV (PLWH) with a new diagnosis of KS made between 2016 and 2019 at primary care facilities in Kenya and Uganda using rapid case ascertainment. In a cohort study, they were subsequently followed for survival.</p><p><strong>Results: </strong>Among 411 participants with new KS diagnoses, 71% were men, median age was 34 (IQR: 30-41) years, and 91% had advanced KS. Over a median follow-up of 7.8 (IQR: 2.4-17.9) months, cumulative incidence of death (95% CI) at months 6, 12 and 18 were 34% (30%-39%), 41% (36%-46%) and 45% (40%-51%), respectively. At time of KS diagnosis, having the highest number of anatomic sites (11 to 16) with KS lesions compared to 1 to 3 sites (hazard ratio (HR)=2.2; 95% CI: 1.3-3.8), presence of oral lesions (HR=2.2; 95% CI: 1.4-3.3), lower hemoglobin, lower CD4 count and higher plasma HIV RNA viral load were associated with higher mortality.</p><p><strong>Conclusion: </strong>Among adult PLWH with new KS diagnoses in East Africa in the \"Treat All\" era, survival was poor and related to mucocutaneous extent of KS. The findings support need for better control of KS in Africa, including novel approaches for earlier detection, linkage to oncologic care, and more potent therapy.</p>","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144736559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stigma-related disclosure concerns and negative self-image have not improved over a decade in older people with HIV.","authors":"Kevin Moody, Myrthe L Verburgh, Sarah E Stutterheim, Maarten F Schim Van Der Loeff, Peter Reiss, Pythia T Nieuwkerk, Suzanne E Geerlings, Marc van der Valk","doi":"10.1097/QAI.0000000000003732","DOIUrl":"https://doi.org/10.1097/QAI.0000000000003732","url":null,"abstract":"<p><strong>Objective: </strong>Stigma impedes the HIV care continuum and contributes to problematic mental health outcomes, non-adherence and reduced quality of life. We prospectively analysed changes in HIV stigma measures over 10-years among older people with HIV (PWH).</p><p><strong>Design: </strong>PWH participating in the AGEhIV Cohort Study completed the full Berger HIV Stigma Scale (HSS) between 2012-2014 (T0) and two of the HSS subscales - i.e. disclosure concerns and negative self-image (range per subscale: 3 to 12) - 10 years later (T1) as part of routine clinical care.</p><p><strong>Methods: </strong>We assessed changes in scores over time using paired samples t-tests. We assessed sociodemographic and clinical factors associated with these changes at T1 using linear regression, and factors associated with higher or lower scores over time using linear mixed models.</p><p><strong>Results: </strong>Disclosure concerns scores decreased significantly, albeit minimally, between T0 and T1; negative self-image scores remained stable. No factors were associated with changes in disclosure concerns scores. Higher disclosure scores were positively associated with living in households with 3 or more people. Women experienced significantly higher increases in negative self-image scores. Higher self-image scores were associated with being attracted to both men and women, compared to only men, and having moderate to severe depressive symptoms. Both HSS domains were negatively associated with more years since HIV diagnosis.</p><p><strong>Conclusion: </strong>In this cohort of predominately older, white, Dutch male PWH mostly with suppressed HIV, disclosure concerns and self-image did not improve over time. HIV stigma worsened in women and was lower for those in large households and with moderate to severe depression.</p>","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144736558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of the targeted universal tuberculosis testing care cascade among people with HIV in PEPFAR-supported districts in South Africa.","authors":"Katlego Motlhaoleng, Kgomotso Vilakazi-Nhlapo, Kate Shearer, Jonathan E Golub, Gary Maartens","doi":"10.1097/QAI.0000000000003729","DOIUrl":"https://doi.org/10.1097/QAI.0000000000003729","url":null,"abstract":"","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IgG and Fc receptor genetic variation associates with functional antibody responses in a DNA and protein candidate HIV vaccine trial.","authors":"Haleigh Conley, Song Young Oh, Nigel Garrett, James Kublin, Cynthia L Monaco, Spencer Watts, Shalini Jha, Guido Ferrari, Georgia D Tomaras, Daniel E Geraghty, Cliburn Chan, Justin Pollara","doi":"10.1097/QAI.0000000000003734","DOIUrl":"https://doi.org/10.1097/QAI.0000000000003734","url":null,"abstract":"<p><strong>Background: </strong>The HVTN108 trial evaluated the safety and immunogenicity of a DNA prime, adjuvanted protein boost HIV vaccine in the US and South Africa. The underlying factors influencing individual variation in vaccine responsiveness are unknown. Here, we defined the IgG Fc and Fc receptor (FcR) genotypes in the HVTN108 cohort to test our hypothesis that IgG and FcR genetic variation can affect vaccine-elicited functional antibody responses.</p><p><strong>Methods: </strong>IgG Fc and FcR alleles were determined by targeted PCR amplification and next-generation sequencing. Vaccine-elicited functional antibody responses, including binding antibody multiplex assay (BAMA), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) activity were measured utilizing standardized and qualified methods. Relationships between alleles and antibody responses were identified by linear regression controlling for treatment group and region.</p><p><strong>Results: </strong>The distribution of many polymorphisms significantly differed between the US and South Africa. Within the subset of the cohort tested for functional antibody responses (IgG, n=41; FcR, n=55), IgG genotypes such as IGHG1*12 (p=0.012), IGHG3*11 (p=0.033), IGHG2*02 (p=0.038), IGHG4*07 (p=0.076), and others were associated with ADCC antibody responses when corrected for vaccine group and regional effects. In the same way, we identified that the FCER1A rs2427827 mutation had a significant association with lower peak ADCC activity and the FCER2 rs2228137 mutation was associated with lower antibody binding to Con6 gp120 protein.</p><p><strong>Conclusion: </strong>Genetic variation in both antibodies and FcRs associated with levels of HIV- vaccine-elicited functional antibodies. Significant regional differences in distribution of this variation support the need for vaccine testing in diverse populations.</p>","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Rapid Restart among People with Previously Diagnosed HIV at a Safety-Net HIV Clinic in San Francisco.","authors":"Jorge Salazar, Susa Coffey, Jessica Bloome, Matthew D Hickey, Lisa Fleming, Salvador Franco, Anthony Suarez, Diane Havlir, John A Sauceda, Monica Gandhi, Katerina A Christopoulos","doi":"10.1097/QAI.0000000000003727","DOIUrl":"https://doi.org/10.1097/QAI.0000000000003727","url":null,"abstract":"<p><strong>Background: </strong>Little is known about outcomes of rapid restart of antiretroviral therapy (ART) among people with HIV re-linking to care.</p><p><strong>Setting: </strong>Safety-net HIV clinic in San Francisco.</p><p><strong>Methods: </strong>Using electronic medical record data, we conducted a retrospective study of adults with HIV (≥18 years old, out of care, self-reported off ART) seen for rapid (same-day) restart of ART. Descriptive statistics summarized baseline sociodemographic and clinical variables. Chi-square and Fisher's exact tests assessed associations between sociodemographic or clinical variables and two primary outcomes: 1) viral suppression (VS) (HIV viral load <200 copies/mL) within 180 days, and 2) sustained re-engagement in care (≥1 primary care provider visit both within 90 and 91-180 days after rapid restart). Complete case VS analysis included those with baseline viremia and follow-up HIV viral loads (VLs). In sensitivity analysis, those with missing follow-up VLs were considered non-suppressed.</p><p><strong>Results: </strong>Between August 2020-October 2023, 141 adults (median age 42 years; 85% cis-male; 26% Latino/a) presented for rapid restart. Housing instability/homelessness (46%), substance use (61%), and mental illness (49%) were common. Among those with baseline viremia who returned for follow-up VLs, VS was attained in 79% and associated significantly with non-Latino/a ethnicity (87% non-Latino/a vs. 57% Latino/a, p=0.004). However, VS was 58% when considering missing follow-up VLs as non-suppressed. Sustained re-engagement in care was observed in only 33%.</p><p><strong>Conclusion: </strong>Following rapid restart, sustained re-engagement in care and VS were low. Evaluation of key processes of rapid restart, retention efforts, and studies on effective re-engagement support strategies are needed.</p>","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV incidence, migration and diagnosis dynamics, France, 2012-2023: a surveillance and modeling data analysis.","authors":"Amber Kunkel, Amadou Alioum, Florence Lot, Françoise Cazein","doi":"10.1097/QAI.0000000000003730","DOIUrl":"https://doi.org/10.1097/QAI.0000000000003730","url":null,"abstract":"<p><strong>Background: </strong>In France, new HIV diagnoses have declined since 2012 among native-born men who have sex with men (MSM) but not among MSM or heterosexuals born abroad. We aimed to disentangle and describe trends in HIV incidence in France, migration of undiagnosed people living with HIV (PLHIV), and diagnosis delays among people born abroad.</p><p><strong>Setting: </strong>France.</p><p><strong>Methods: </strong>We applied a mathematical model that estimates individual-level diagnosis delay distributions and identifies likely pre-migration infections to surveillance data of new HIV diagnoses from France. We then applied a second model to estimate HIV incidence in France and the number of arriving migrants with pre-migration infections each year from 2012-2023. Denominators were estimated from official population statistics.</p><p><strong>Results: </strong>The number of undiagnosed PLHIV arriving in France fell sharply during the COVID-19 pandemic before resuming previous trends; HIV incidence showed no such effect. Excluding this period, overall HIV incidence and migrations of undiagnosed PLHIV have been stable among people from sub-Saharan Africa (SSA) despite increasing immigration. However, they have increased among MSM born in SSA and other foreign countries. People with pre-migration infections are diagnosed at a later clinical stage of infection than people born in France, but generally within one year of arrival; people with post-migration infections have diagnosis delays similar to those born in France. Only 15% of undiagnosed PLHIV were infected pre-migration.</p><p><strong>Conclusion: </strong>Progress in HIV prevention among people born abroad has been mixed. Preventing and diagnosing post-migration infections are key to preventing onward transmission.</p>","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the Impact of Antiretroviral Therapy and Other Factors on HPV Clearance in Cisgender Women with HIV/HPV Co-infections in the DC Cohort.","authors":"Halah G Jadallah, Lauren F O'Connor, Morgan Byrne, Anuja Baskaran, Michael Horberg, Amanda D Castel, Anne K Monroe","doi":"10.1097/QAI.0000000000003726","DOIUrl":"10.1097/QAI.0000000000003726","url":null,"abstract":"<p><strong>Background: </strong>Women with HIV are at an elevated risk for HPV. Antiretroviral therapy (ART) effectively treats HIV; however, there is no non-invasive pharmacological treatment for HPV. Previous studies have shown varied effects of ART class on HPV clearance, with some demonstrating an association. Our objective was to evaluate the association between ART class and HPV clearance among women with HIV/HPV co-infections.</p><p><strong>Methods: </strong>We analyzed electronic health records from participants with HPV in the DC Cohort Longitudinal HIV Study from time at HPV detection to January 1, 2024. We investigated time to HPV clearance based on time-updated ART status using Cox proportional hazards and Kaplan Meier models, focusing on protease inhibitors (PIs) and integrase strand transfer inhibitors (INSTIs).</p><p><strong>Results: </strong>Among 362 women with HIV/HPV co-infections, 94.8% were Non-Hispanic Black, 81.2% had public insurance, and 45.6% were smokers. Overall, 74.0% cleared their HPV infection. A higher proportion of participants who cleared HPV were on PIs at baseline compared to those who did not (p=0.03). Those who did not achieve clearance had lower nadir CD4 counts (p=0.04) and did not achieve viral suppression (p=0.0005). In the survival analysis, women on PI-based regimens had shorter time to HPV clearance compared to those on INSTIs (HR = 2.12, 95% CI: 1.39, 3.24).</p><p><strong>Conclusion: </strong>This study suggests that PIs may be associated with a higher likelihood of HPV clearance among women with HIV. Our results provide evidence on the influence of clinical and sociodemographic factors, including ART, that may affect HPV clearance among women with HIV.</p>","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults with HIV with and without genotypic resistance testing results. 96-Week effectiveness and tolerability of REDOLA study.","authors":"Alfonso Cabello-Ubeda, Juan Carlos López Bernardo de Quirós, Álvaro Mena, Miguel Torralba, Luz Martín Carbonero, Ángela Gutiérrez, Jorge Vergas, Adriana Pinto, Francisco Tejerina, Esmeralda Palmier, Jesús Sanz, Miguel Górgolas, Federico Pulido","doi":"10.1097/QAI.0000000000003721","DOIUrl":"https://doi.org/10.1097/QAI.0000000000003721","url":null,"abstract":"","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV testing among transgender and other gender diverse persons in the United States: A scoping review.","authors":"Jake Anders, Anthony Freeman, Baichun Hou, Philippa Sone, Jasmine Lopez-Phelan, Patrick Padgen, Rebecca Giguere, Cam Gowdicott, Shima Ge, Alyson Clarke, Cristina Herrera, Zoe Edelstein, Theo G M Sandfort","doi":"10.1097/QAI.0000000000003728","DOIUrl":"https://doi.org/10.1097/QAI.0000000000003728","url":null,"abstract":"<p><strong>Background: </strong>An overview of existing research on HIV testing among transgender and other gender diverse (TGD) populations in the United States is missing, while critical for informing future interventions and research.</p><p><strong>Methods: </strong>Employing the Preferred Reporting Items for Systematic Reviews and Meta-Analysis, three databases (CINAHL, PubMed/Medline, PsycINFO) were searched for studies reporting in English on HIV testing behavior that focused on or included TGD persons, published in the last decade (February 2, 2013 to February 2, 2023). Twenty-six studies were included and extracted using Covidence.</p><p><strong>Results: </strong>Four topics regarding HIV testing among TGD persons were identified: prevalence of HIV testing compared with cisgender persons, testing frequency and associated factors among TGD persons, barriers and facilitators to HIV testing experienced by TGD persons, and testing modalities. TGD persons seemed more likely to have been tested for HIV compared to cisgender persons, but less frequent compared to cisgender men who have sex with men. Barriers to testing included availability, confidentiality concerns, and negative interactions with providers. Social support and gender-affirming care were seen as facilitators. Self-testing, although not common, was acceptable and preferred when available. The conceptualizations and operationalizations of the term transgender varied markedly across studies.</p><p><strong>Conclusions: </strong>Our understanding of HIV testing practices in TGD populations is limited and shows serious gaps. Research on repeat testing is needed to enhance HIV prevention and care among TGD populations. Future research might benefit from theory-driven approaches and from involving TGD persons in the design and implementation of studies to ensure relevance and efficacy.</p>","PeriodicalId":520658,"journal":{"name":"Journal of acquired immune deficiency syndromes (1999)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}